Bayer: reduced dose gadobutrol effective in MRI
(CercleFinance.com) - Bayer today published the results of a Phase IV study showing the clinical efficacy of a reduced dose of gadobutrol, compared to a standard dose of gadoterate, in patients undergoing steady-state contrast MRI of the central nervous system.
As such, the total number of lesions detected per average reading was 301 for gadobutrol, versus 291 for gadoterate.
The study's data were presented at this year's European Society of Neuroradiology (ESNR) hybrid annual meeting, which is being held in Geneva until 3 October 2021.
Copyright (c) 2021 CercleFinance.com. All rights reserved.